Creative BIolabs is glad to release its technique—human antibody production from transgenic mice.
SHIRLEY, N.Y. - Oct. 21, 2015 - PRLog -- Creative Biolabs has developed the Fully Human Antibody Technology™ (FHAT) to produce fully human monoclonal antibodies in mice. As a custom service provider in the field of human antibody production, Creative Biolabs has in-licensed two strains of "humanized" transgenic mice (FHAT mice) and successfully demonstrated their applications in discovery and production of unique fully human antibodies against various targets.
By introducing human immunoglobulin loci into the germ line of mice with inactivated mouse antibody machinery, the in-licensed mouse strains can directly generate high-affinity, fully human antibodies, which avoid the subsequent cost and tedious in vitro affinity maturation as well as antibody humanization process. In terms of immunization, the immunoglobulin transgenes undergo V(D)J joining, random nucleotide (N region) addition, class switching and somatic mutation so as to generate monoclonal antibodies with high affinity.
Since the first EGFR targeting antibody panitumumab (Vectibix) from humanized mice has obtained regulatory approval in 2005, dozens of additional transgenic mouse-derived mAbs have entered the phase of human clinical testing, i.e., CD20 (Ofatumumab), CD4 (Zanolimumab), CD70 (MDX-1411), etc. These genetically "humanized" mouse strains have become an extremely powerful toolbox for antibody drug discovery.
"The FHAT transgenic mice genetically engineered with a "humanized humoral immune" system can be of better valuable in therapeutic antibody development, since the derivative antibodies are preselected in vivo," said Monica Müller, scientific officer of Creative Biolabs.
In contrast, antibodies derived from non-animal sources have artificial antibody sequences that do not exist in nature. These non-nature-selected antibody sequences may perform well in vitro but will behave completely different in vivo. One of the common problems is that the artificial antibodies will disappear in vivo without disclosing their whereabouts. This could be due to the fact that the antibodies are bound to unknown epitopes. Alternatively, the antibodies are captured by cells or simply degraded or sliced in vivo. Antibodies derived from live animals have passed nature-selection and usually do not have such issues.
Learn more details about human antibody production from transgenic mice.
About Creative Biolabs
Creative Biolabs is a custom service provider in the field of antibody production and antibody engineering. Its service portfolio includes mouse and rat monoclonal antibody production (using hybridoma technology, human, monkey, rabbit, chicken, dog, llama) and camel monoclonal antibody production (using various antibody library technologies including phage display, bacterial display and yeast display). It also conducts in depth antibody humanization and affinity maturation with phage display and DNA mutagenesis approaches.
Learn more about Creative Biolabs.
Photos: (Click photo to enlarge)
Read Full Story - Creative Biolabs Releases Human Antibody Production from Transgenic Mice | More news from this source
Press release distribution by PRLog
Creative Biolabs Releases Human Antibody Production from Transgenic Mice
October 21, 2015 at 05:42 AM EDT